| Byram Healthcare Centers Inc | |
| 31000 Lahser Rd, Ste 6, Beverly Hills, Michigan 48025 | |
| (248) 594-0810 |
| Name | Byram Healthcare Centers Inc |
|---|---|
| Organization Name | Byram Healthcare Centers, Inc |
| Location | 31000 Lahser Rd, Ste 6, Beverly Hills, Michigan 48025 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (248) 594-0810 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A Phase III trial of a drug used for the treatment of vitreomacular adhesion and macular hole revealed key findings for patients diagnosed with these severe conditions which can lead to significant vision impairment.
Approximately 25 percent of eyes deemed to be normal based on dilated eye examination by a primary eye care ophthalmologist or optometrist had macular characteristics that indicated age-related macular degeneration, according to a study published by JAMA Ophthalmology.
A new study has shown that myricitrin, a flavinoid with antioxidant and anti-inflammatory activity that is present inedible plants and fruit, can protect mouse brains from the loss of dopamine-producing neurons caused by neurotoxicity.
AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.
› Verified 2 days ago
| NPI Number | 1700089653 |
| Organization Name | BYRAM HEALTHCARE CENTERS, INC. |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 31000 Lahser Rd, Suite 6, Beverly Hills, MI 48025 |
| Phone Number | 248-594-0810 |
News Archive
A Phase III trial of a drug used for the treatment of vitreomacular adhesion and macular hole revealed key findings for patients diagnosed with these severe conditions which can lead to significant vision impairment.
Approximately 25 percent of eyes deemed to be normal based on dilated eye examination by a primary eye care ophthalmologist or optometrist had macular characteristics that indicated age-related macular degeneration, according to a study published by JAMA Ophthalmology.
A new study has shown that myricitrin, a flavinoid with antioxidant and anti-inflammatory activity that is present inedible plants and fruit, can protect mouse brains from the loss of dopamine-producing neurons caused by neurotoxicity.
AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.
› Verified 2 days ago
News Archive
A Phase III trial of a drug used for the treatment of vitreomacular adhesion and macular hole revealed key findings for patients diagnosed with these severe conditions which can lead to significant vision impairment.
Approximately 25 percent of eyes deemed to be normal based on dilated eye examination by a primary eye care ophthalmologist or optometrist had macular characteristics that indicated age-related macular degeneration, according to a study published by JAMA Ophthalmology.
A new study has shown that myricitrin, a flavinoid with antioxidant and anti-inflammatory activity that is present inedible plants and fruit, can protect mouse brains from the loss of dopamine-producing neurons caused by neurotoxicity.
AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.
› Verified 2 days ago
Byram Healthcare Centers Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 31000 Lahser Rd, Beverly Hills, Michigan 48025 Phone: (248) 594-0810 |